Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Minimal interaction between gatifloxacin and oxycodone.

Edward M Grant1, David R Nicolau, Charles Nightingale

  • 1Department of Pharmacy Research, Hartford Hospital, Connecticut 06102-5037, USA.

Journal of Clinical Pharmacology
|August 7, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bictegravir/emtricitabine/tenofovir alafenamide plus doravirine in highly treatment-experienced men with multidrug-resistant HIV.

AIDS (London, England)·2023
Same author

Relative bioavailability of crushed tebipenem administered through a nasogastric tube with and without enteral feeding.

The Journal of antimicrobial chemotherapy·2022
Same author

Mosquito Exposure and Chikungunya and Dengue Infection Among Travelers During the Chikungunya Outbreak in the Americas.

The American journal of tropical medicine and hygiene·2017
Same author

Treatment of multidrug-resistant Pseudomonas aeruginosa with ceftolozane/tazobactam in a critically ill patient receiving continuous venovenous haemodiafiltration.

International journal of antimicrobial agents·2016
Same author

Assessment of Clostridium difficile Burden in Patients Over Time With First Episode Infection Following Fidaxomicin or Vancomycin.

Infection control and hospital epidemiology·2015
Same author

Predictors for physical activity in adolescent girls using statistical shrinkage techniques for hierarchical longitudinal mixed effects models.

PloS one·2015
Same journal

Population Pharmacokinetic Modeling and Simulation to Support the Regulatory Submission of the Two-Injection Start Regimen with Aripiprazole Once-Monthly Long-Acting Injectable Intramuscular Administration in Japanese Patients with Schizophrenia or Bipolar I Disorder.

Journal of clinical pharmacology·2026
Same journal

External Evaluation of Population Pharmacokinetic Models for Factor VIII in Chinese Patients with Hemophilia A.

Journal of clinical pharmacology·2026
Same journal

How to Replace the TQT Study-The Use of Concentration-QTc Modeling to Exclude a Small Effect of a Novel Drug on QT Interval: Historical Perspective and Implementation.

Journal of clinical pharmacology·2026
Same journal

Genome Sequencing Enhances Precision and Clinical Utility of Pharmacogenetic Data Compared to Arrays.

Journal of clinical pharmacology·2026
Same journal

FDA Gene Therapy Approvals (1998-2025): Current Status, Regulatory Evolution, and Future Directions.

Journal of clinical pharmacology·2026
Same journal

Human Disposition, Metabolism, and Excretion of Sevasemten (EDG-5506), a Selective Modulator of Fast Myosin in Healthy Volunteers.

Journal of clinical pharmacology·2026
See all related articles

Concomitant administration of oral oxycodone and gatifloxacin does not significantly impact gatifloxacin bioavailability. This finding is crucial for understanding drug interactions and ensuring effective treatment regimens.

Area of Science:

  • Pharmacology
  • Drug Interactions
  • Clinical Pharmacology

Background:

  • Previous research indicated reduced oral bioavailability of fluoroquinolones (e.g., trovafloxacin, ciprofloxacin) when taken with intravenous opiates like morphine.
  • This interaction led to decreased AUC (area under the curve) and potential clinical treatment failures.

Purpose of the Study:

  • To investigate potential drug interactions between oral oxycodone and gatifloxacin.
  • To determine if co-administration affects gatifloxacin's oral bioavailability.

Main Methods:

  • A randomized, open-label, two-way crossover study involving twelve healthy volunteers.
  • Participants received either oxycodone (5 mg every 4 hours) and gatifloxacin (400 mg) or gatifloxacin alone.
  • Pharmacokinetic parameters, including AUC, Cmax, and Tmax, were assessed via blood sampling over 24 hours.

Related Experiment Videos

Main Results:

  • No statistically significant differences were observed in the AUC and Cmax of gatifloxacin when administered with or without oxycodone (p > 0.05).
  • However, the Tmax (time to reach maximum concentration) for gatifloxacin was significantly delayed when co-administered with oxycodone (p < 0.001).

Conclusions:

  • Oral oxycodone and gatifloxacin can be administered together without a significant reduction in gatifloxacin's overall bioavailability.
  • While absorption rate (Tmax) is affected, the total drug exposure (AUC) remains comparable, suggesting clinical safety for this combination.